Objectives Terminalia catappa has shown potent antidiabetic activity in the past; however, the exact molecular mechanisms by which it acts have not been elucidated. This review aims at exploring several hypotheses which have been proposed to explain its mechanism of action, including reduction in oxidative stress, inflammation, angiogenesis, lipid profile correction and direct hypoglycaemic actions. Methods A thorough review of all the articles, research as well as reviews, available regarding the concerned topic was performed. MEDLINE databases were searched using keywords (and their combinations), such as T. catappa, renin oxidative stress, inflammation, angiogenesis, diabetic retinopathy, a-glucosidase and a-amylase, among several others. English-language articles were preferably selected. Key findings Apart from metabolic dysfunctions, several hyperglycaemiainduced pathological conditions come into scene as the after-effects of diabetes. These mainly include inflammation, oxidative stress, angiogenesis and lipid profile alteration, which ultimately result in vascular endothelial dysfunction, hepatic steatosis, lipid peroxidation and apoptosis of endothelial, hepatic and neuronal cells. Terminalia catappa effectively attenuates the progression of diabetic retinopathy and shows significant hypoglycaemic actions. The mechanisms behind these effects were explained. Conclusion Terminalia catappa may provide an effective natural product to treat hyperglycaemia and prevent subsequent diabetic complications.
Introduction
Diabetes mellitus is one of the most widespread disorders worldwide. It is a chronic, life-long, endocrine dysfunction affecting millions of people every year. With the increasing fraction of population getting affected, it has become a matter of great concern to explore novel ways to prevent/ treat this disorder. Although conventional therapy is efficacious and satisfactory, there is a growing need to develop therapies from natural products to prevent the side effects of synthetic drugs. This has shifted the focus of researchers on exploring various plants having antidiabetic properties. Till date, the following plants have been confirmed to possess antidiabetic activity -Allium sativum, Gymnema sylvestre, Citrullus colocynthis, Trigonella foenum greacum, Momordica charantia, Ficus bengalensis, Annona squamosa, for congestive heart failure and is preferred over any other chemical compound eliciting positive ionotropic effect. Hence, optimization and standardization of natural products may lead to their efficacious and judicious clinical use (Figures 1 and 2) .
Apart from the list mentioned above, another plant eliciting antidiabetic activity is Terminalia catappa. Several animal studies have been conducted in the past decade to explore its antidiabetic potential. They concluded that it effectively reduces the fasting blood glucose levels, serum cholesterol, serum triglycerides, serum low-density lipoprotein (LDL), serum creatinine, serum urea and serum alkaline phosphatase levels in diabetic animal models. [3] Apart from antidiabetic properties, several studies conducted in the past have reported a number of other uses of different extracts of T. catappa, for example, antimicrobial property of aqueous and methanol extract of leaves, [4] antibacterial property of aqueous extract of leaves, [5] anti-inflammatory action of ethanolic extract of leaves, anti-HIV reverse transcriptase activity of ethanolic extract of leaves, aphrodisiac effects of suspension of the kernel, [6] modulatory properties of methanolic extract of leaves, analgesic activity of ethanolic extract of leaves, wound healing action of chloroform extract of bark, antioxidant and radical scavenging activity of aqueous extract of leaves, hepatoprotective effects of chloroform extract of leaves, anticancer property of ethanolic extract of leaves, antimutagenic activity of aqueous extract of leaves and antiageing property of aqueous extract of leaves. [7] However, the exact molecular mechanisms behind the activity still need to be explained. Many hypothetical mechanisms have been proposed to demonstrate the effect of administration of T. catappa leaf/bark/seed extract on various pathological conditions induced during hyperglycaemia. Knowledge of these mechanisms would probably make it easier for the plant extract to be potentially utilized as a clinical treatment for hyperglycaemia and associated diabetic complications. This review is one of the first of its kind as no such detailed discussion about the molecular mechanisms of action of T. catappa is available in the literature (Table 1) .
Diabetes mellitus and its associated complications
Diabetes mellitus is a chronic metabolic disorder characterized most commonly by abnormally elevated blood glucose levels. It occurs as a result of a series of events following either decreased insulin secretion or impaired insulin [8] Based on the region affected, these complications are named accordingly, for example if retinal vasculature is affected, it is termed as diabetic retinopathy. Similarly for kidney, neurons and heart, the complications are named as diabetic nephropathy, diabetic neuropathy [8] and diabetic cardiomyopathy, respectively. [9] These complications are traditionally classified under two categories -microvascular and macrovascular, depending upon the size of the blood vessel affected. Diabetic retinopathy, diabetic nephropathy and diabetic neuropathy are classified under microvascular complications and are mainly due to oxidative stress, inflammation and angiogenesis, while the main pathology behind the macrovascular complications is atherosclerosis (which again is due to chronic inflammation). After conducting numerous studies, the researchers have postulated several mechanisms which tend to explain hyperglycaemiamediated effects that lead to the progression of diabetic complications. These include hyperglycaemia-induced increased flux of polyol pathway, increased production of advanced glycation end products, overactivation of protein kinase C (PKC), oxidative stress, angiogenesis and inflammation, among various others. [10, 11] The combined effects of above-mentioned pathological occurrences adversely affect cellular structure and function and hence play a central role in the pathophysiology of almost all diabetic complications.
Oxidative stress refers to a condition caused by imbalance in the levels of free radicals and radical scavengers. It may either occur when the formation of free radicals exceeds the scavenging capacity of the endogenous antioxidants or the concentration of the latter falls beyond the level required to produce sufficient protective effects. Hyperglycaemia leads to oxidative stress by upregulating glycolysis and citric acid cycle, during which formation of NADH and FADH 2 takes place. As both NADH and FADH 2 subsequently take part in the mitochondrial electron transport chain, their increased formation upregulates this process, leading to excessive production of superoxide radical. [12, 13] Hyperglycaemia-induced oxidative stress further induces the flux of polyol pathway, overexpression of RAGE (receptor for advanced glycation end products), upregulate PKC-mediated inflammatory responses and activate apoptotic factors such as caspases, cytochrome C, apoptosis-inducing factor (AIF) and apoptotic proteaseactivating factor-1 (APAF-1). These factors cause apoptosis of retinal pigment epithelium and renal mesangial cells. Activation of PKC leads to induction of various inflammatory mediators such as VEGF (vascular endothelial growth factor), TGF-beta 1 (transforming growth factor-beta 1), PAI-1 (plasminogen activator inhibitor-1) and NF-jB (nuclear factor-kappa B) which demyelinate the neurons and cause diabetic neuropathy. [13] Besides, free radicals damage cellular membranes directly by initiating lipid peroxidation. [14] Angiogenesis is the de novo formation of new blood vessels on pre-existing vasculature. It holds great pathological significance in diabetic retinopathy and diabetic nephropathy. Combination of angiogenesis and inflammation make vasculature extremely vulnerable to physical, biochemical and oxidative stress-induced damage. As the newly formed blood vessels are fragile in nature, their exposure to highly pathological environment (comprising of elevated levels of pro-inflammatory mediators and reactive oxygen species) prevalent during hyperglycaemia damages the premature endothelial cells, causing them to leak out their contents. This results in oedema which further invites more inflammatory responses. Neovascularization and macular oedema are characteristic features of diabetic retinopathy [15] while glomerular basement membrane thickening and mesangial expansion complementary counterparts in diabetic nephropathy. [16] All these events are mediated by angiogenesis and associated inflammation. VEGF is the most potent pro-angiogenic agent involved in the mentioned responses, while others include insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), basic fibroblast growth factor (b-FGF), platelet-derived growth factor (PDGF), pro-inflammatory cytokines and angiopoietins. [15] During hyperglycaemia, VEGF is mainly activated via stimulation of PKC, HIF-1-a (hypoxia-inducible factor-1-alpha) and reactive oxygen species, and regulates both angiogenic and inflammatory responses by upregulating circulation of endothelial progenitor cells (EPCs), and inducing the expressions of cellular adhesion molecules, other proinflammatory mediators and matrix metalloproteinases (MMPs). [17] Increased lipid content also plays a key role in the pathophysiology of diabetes and its complications. Obesity is also directly related to increased inflammation owing to the recruitment of macrophages by adipocytes-released macrophage chemoattractant protein-1 (MCP-1). The recruited macrophages release a variety of pro-inflammatory mediators, among which cytokines such as TNF-a and interleukins (mainly IL-6 and IL-1b) are the main pathological players as they further induce numerous other factors which aggravate inflammation. Besides, macrophage recruitment in hepatocytes is one of the mechanisms of induction of insulin resistance due to the activation of JNK/SAPK pathway which causes hepatic steatosis, lipid peroxidation and hepatic apoptosis, thus making hepatocytes (one of the major target cells for insulin) insensitive towards insulin stimulus. [18, 19] This clearly indicates that high lipid content (LDL cholesterol and total cholesterol levels) may contribute greatly in the development of type-2 diabetes mellitus. Besides, deposition of lipids in kidney predisposes glomerular cells to hyperglycaemia-induced inflammation, increasing the risk of diabetic nephropathy. [20] Hence, the above-mentioned complex interplay of oxidative stress, inflammation, angiogenesis and high lipid content describes the mechanisms which facilitate the progression of diabetes to various diabetic complications. Any agent which could target all these pathological events at once, and at the same time lowers blood glucose levels, is required to treat hyperglycaemia and completely suppress its progression into subsequent diabetic complications.
Terminalia catappa and its phytochemistry
Terminalia catappa Linn. (Family -Combretaceae) is a south-east Asian plant found mainly in tropical regions. It grows well in subtropical and tropical climates and predominately inhabits the coastal regions. Indian varieties are commonly known by the names -Indian almond, Malabar almond and Tropical almond. [21] It is a widely acknowledged plant in traditional medicines, and its bark, seed, fruit and leaf extracts show numerous beneficial properties in the treatment of various disorders. Phytochemical studies have revealed the presence of a wide range of phytoconstituents in different parts of T. catappa. These include alkaloids, flavonoids, polyphenols, saponosides, sterols, carbohydrates, proteins, carotenoids (b-carotene), fat, vitamins, triterpenes, thiocyanates, cardiac glycosides, cyanogenic glycosides and para-hydroxybenzoic acid. [7, 21, 22] Among these, phenolic compounds, tannins, flavonoids, carotenoids and triterpenes/triterpenoids are present in abundance and are thought to elicit a number of utilizable responses (such as anti-inflammatory, antiangiogenic, antioxidant, hypocholesterolaemic and hypoglycaemic). Besides, some studies have reported that alkaloids and sterols derived from T. catappa also show similar properties. [7, 21] The qualitative details of the various phytochemicals present in T. catappa are given as follows: 1 Chemical nature • Triterpenes/Triterpenoids: ursolic acid, 2,23-dihydroxy ursolic acid, 2-alpha, 3-beta, 23-trihydroxyurs-12-en-28-oic acid (DHUA), [23] squalene [24] and asiatic acid
• Carotenoids: b-carotene • Vitamins: vitamin C and vitamin E 2 Part from which they are obtained
• Bark: catappanin, 2 phenolcarboxylic acids, 2 phenolic glycoside gallates, 7 ellagic tannins, 4 flavan-3-ols, [7, 21, 25] 
two triterpenoid saponins (chebuloside II, arjunoglucoside II), two triterpenes (arjunolic acid and 3-betulinic acid) and sitosterol-3-O-b-D-glucopyranoside, [26] glycoside, volatile oils, saponin and steroid
• Seed: fixed oil, moisture, oleic acid, palmitic acid, myristic acid, stearic acid, linoleic acid, palmitoleic acid, arachidic acid, proteins, ash, fat, carbohydrate, calcium, magnesium, potassium and sodium, phosphorus, iron, fibre, b-carotene, ascorbic acid, niacin, riboflavin, thiamin, and water.
• Leaves: b-carotene, a-tocopherol, p-hydroxybenzoic acid, punicalagin and its derivatives, asiatic acid, ursolic acid, 4-hydroxyphenylpropionic acid, quercetin, kaempferol, m-coumaric acid, 3,4-dihydroxybenzoic acid, p-coumaric acid, gallic acid, saponins, phytosterols, ash, protein, glucose, moisture, carbohydrate and oil (unsaturated fatty acids, predominantly oleic acid and linoleic acid)
• Fruit: glucose, pentosans, corilagin, brevifolin carboxylic acid, b-carotene, cyanidin-3-glucoside, ellagic acid, gallic acid and tannin. [7, 21, 25] Mechanisms for antidiabetic actions of Terminalia catappa A number of beneficial properties of T. catappa are reported, as already discussed, including antidiabetic actions. However, a deeper exploration is needed to illustrate the mechanism by which it reduces hyperglycaemia and prevents the progression of various diabetic complications. Some hypotheses regarding the mechanism of action of several phytoconstituents eliciting protective actions against hyperglycaemia and hyperglycaemia-induced pathological conditions are discussed as follows:
Terminalia catappa reduces oxidative stress Studies carried out on T. catappa to explore its hepatoprotective activity, antimetastatic activity and anticlastogenic activity in the last decade have confirmed that the plant extract attenuates oxidative stress. This activity has been attributed to its free radical scavenging capability, [27, 28] which may be potentially utilized to suppress hyperglycaemia-induced mitochondrial dysfunction and oxidative stress. Several chemical constituents present in T. catappa exhibit antioxidant properties. In cultured hepatocytes, leaf extract of T. catappa reversed the swelling effect of calcium ions on mitochondria and also dose-dependently scavenged the superoxide radical produced from mitochondria during conditions of oxidative stress under pathological stimuli. The phytochemical principle performing this activity was identified as 2a, 3b, 23-trihydroxyursane-12-en-28-oic acid (DHUA), commonly known as 2, 23-dihydroxy ursolic acid. [23] Besides, two other triterpenoids -namely ursolic acid and asiatic acid -were also identified in the leaf extract of T. catappa for exhibiting similar antioxidant properties. These triterpenoids prevent mitochondrial damage and scavenge superoxide radical and hydroxyl radical. [29] Noticing the hepatoprotective actions of T. catappa due to the antioxidant properties of its chemical constituents, it was speculated that similar shielding effect against oxidative stress might also benefit several other tissues/organs which are adversely affected by excessive free radical production during pathogenesis of certain diseases. In subsequent studies, it was indeed confirmed that ursolic acid exhibits protective actions in pancreatic beta cells. The mentioned action is owed to its immunomodulatory properties, by virtue of which it enhances the function of cellular immune system and downregulates the levels of TNF-a. [30] As TNFa is a potent cytokine whose downstream signalling pathways lead to overproduction of reactive oxygen species in several cells, including mesangial cells, it is considered as a prominent factor responsible for oxidative stress-induced diabetic nephropathy. [31] Hence by inhibiting the TNF-ainduced oxidative stress, ursolic acid might prevent the progression of diabetic nephropathy. Besides, results have shown that the protective actions of ursolic acid on pancreas directly enhance beta-cell function and induce insulin secretion, thereby demonstrating antidiabetic activity. [30] Another chemically related compound, squalene (a triterpene) was isolated from the freeze-dried leaf extract of T. catappa by gas chromatography-mass spectroscopy and high-performance liquid chromatography spiking analyses in supercritical carbon dioxide. [24] Squalene is wellacknowledged as an antioxidant which effectively scavenges singlet oxygen and promotes superoxide dismutase (SOD)-dependent decrease in the production of superoxide radical, thereby preventing lipid peroxidation. Due to the virtue of the stated effects, squalene is of great assistance in the treatment of type-2 diabetes mellitus. [32, 33] Besides, animal models have demonstrated a beneficial role of squalene in maintaining retinal health. Retina, being highly lipoidal, is extremely prone to the effects of reactive oxygen species and undergoes rapid lipid peroxidation in pathological conditions leading to damage of several retinal cells. Antioxidant effects of squalene may prevent the apoptosis of rod outer segment (ROS) disc membranes and rod photoreceptor cells of retina as it is widely transported to the site affected by free radicals. [34] Apart from triterpenoids, several tannins have been extracted from the leaves of T. catappa, among which punicalagin and punicalin are the most copious. Both punicalagin and punicalin, also obtained abundantly from pomegranate juice, are validated potent antioxidant agents. It has been proven that both these phenolic compounds, after getting hydrolysed into gallagic acid, downregulate the production of nitric oxide. [35, 36] In pathological conditions, such as in diabetes mellitus, where the mitochondrial production of superoxide radical is extremely high, nitric oxide reacts with superoxide radical and generates peroxynitrite, a highly reactive species, accountable for inducing cellular apoptosis, further adding to oxidative stress-induced damage. [37] Hence, a decrease in the production of nitric oxide by the tannins obtained from leaf extract of T. catappa under such conditions might greatly benefit in reducing oxidative stress. Besides punicalagin and punicalin, some other tannins such as chebulagic acid and corilagin have portrayed similar antioxidant properties. Not only do they effectively scavenge superoxide radical and peroxyl radicals, but also limit the formation of several reactive oxygen species from leucocytes (such as hydrogen peroxide). This greatly restricts lipid peroxidation, an event which otherwise would greatly accelerate the progression of diabetic retinopathy. [38] Another experiment conducted to explore the antidiabetic properties of T. catappa concluded that apart from preventing the progression and averting further damage to the pancreas, treatment with aqueous and cold extracts of leaves of this plant in alloxan-induced diabetic animal models also showed regeneration of pancreatic beta-islet cells. This cell-regenerating activity was explained by revelation of the presence of b-carotene in T. catappa. The most important mechanism by which b-carotene exhibits this protective action is via preventing glycosylation of proteins. As glycosylated proteins (advanced glycation end products) are one of the prime producers of free radicals, inhibition of their production by b-carotene greatly reduces oxidative stress. [3] The above-listed mechanisms clearly describe the potential of T. catappa in reducing oxidative stress, and hence, it can be used to effectively treat hyperglycaemia and prevent the progression of associated diabetic complications.
Terminalia catappa downregulates inflammatory and angiogenic responses
Anti-inflammatory and antiangiogenic properties of T. catappa have been explored and confirmed by numerous studies. Wide variety of phytochemicals, which includes triterpenoids, phenolic compounds and flavonoids, present in the leaf extract of this plant is accredited for the stated effect. Among triterpenoids, ursolic acid and 2-alpha, 3-beta, 23-trihydroxyurs-12-en-28-oic acid are known to possess the most potent anti-inflammatory properties. [6] The anti-inflammatory and antiangiogenic properties of T. catappa have been demonstrated during the testing of its anticancer potentials. The involvement of same inflammatory and angiogenic mediators in the pathophysiology of diabetes and its related complications allows the exploitation of same inhibitory effects in the latter pathological conditions also. Reduction in the production of TNF-a, a potent cytokine involved in the inflammatory processes seen during diabetes, is the principal mechanism of action of ursolic acid. [39] TNF-a, chiefly produced by macrophages, adipocytes and several other diverse cells, mediates various downstream signalling pathways which ultimately result in inhibition of insulin transduction, leading to insulin resistance. [40] TNF-a-mediated downstream signalling pathways induce the activation of several other pro-inflammatory cytokines and other mediators such as adhesion molecules and nuclear factors. One such mediator includes NF-jB, a nuclear transcription factor responsible for the gene transcription of a number of inflammatory and angiogenic factors among which COX-2 (cyclooxygenase-2), MMP-9 (matrix metalloproteinase-9) and iNOS (inducible nitric oxide synthase) are of our interest. [41] COX-2 acts as a bridge between inflammation and angiogenesis. Acting on arachidonic acid, COX-2 leads to the production of several prostaglandins, among which PGE 2 , a potent pro-inflammatory mediator, stimulates several inflammatory responses involved in the pathophysiology of neurovascular diabetic complications, besides inducing the expression of MMP-9, an extracellular endopeptidase involved in pathological angiogenesis, via stimulating EP-4 receptor axis. [42] MMP-9 has been verified as a pro-angiogenic mediator involved in diabetic retinopathy. Owing to its proteolytic activity, it damages the cells constituting blood-retinal barrier, increasing the permeability of retinal blood vessels and leading to retinal oedema, inflammation and angiogenesis. [43] Besides, downstream signalling of PGE 2 involving EP-2 and/or EP-4 receptor and protein kinase A (PKA) in retina also stimulate the production of VEGF, one of the most potent pro-angiogenic agents known. Its role in inducing neovascularization in the pathophysiology of diabetic retinopathy via stimulating endothelial cell proliferation, migration and tube formation is well-established. [44] Stimulation of iNOS by NF-jB leads to excessive production of nitric oxide, a vasodilator involved in endothelial dysfunction during various microvascular diabetic complications. As during oxidative stress conditions prevalent in hyperglycaemia, nitric oxide is rapidly converted to peroxynitrite (as already discussed in above section), bioavailability of nitric oxide greatly reduces. This predisposes the endothelium to a variety of pathological conditions which otherwise would have been counteracted by nitric oxide, for example increased endothelin production, increased expression of adhesion molecules, leucocyte adhesion and migration, increased platelet adhesion and aggregation, smooth muscle cell proliferation, inflammation and apoptosis. [45] A detailed account of direct downregulatory effect of ursolic acid on NF-jB due to downregulation of TNF-a has been demonstrated by various studies. Ursolic acid suppresses TNF-dependent phosphorylation of IjBa (inhibitor of NF-jB), thereby preventing its degradation. This is mainly mediated by inhibiting TNF-induced IKK (IjB kinase) enzyme activation. Also, ursolic acid inhibits TNFinduced nuclear translocation and phosphorylation of p65 (a subunit of NF-jB necessary for its activation). [41] Owing to the above-mentioned events, ursolic acid greatly reduces the inflammatory and angiogenic responses mediated by TNF-a and NF-jB.
Apart from triterpenoids, phenolic compounds present in T. catappa such as punicalagin also present certain antiinflammatory and antiangiogenic properties. Punicalagin suppresses the expression of TNF-a-induced COX-2, [46] hence reducing the above-mentioned inflammatory and angiogenic responses. Another study showed protective effects of punicalagin in neuroinflammation by interfering with NF-jB-mediated downstream signalling. The mechanism behind this effect has been illustrated as the ability of punicalagin to impair NF-jB-driven luciferase expression and inhibit the phosphorylation of IjBa, p65, mitogenactivated protein kinase (MAPK) including p38, c-Jun N-terminal kinase and extracellular signal-regulated kinase (ERK). [47, 48] This makes T. catappa a potential candidate for keeping a check on the progression of diabetic neuropathy.
A recent study conducted on the T. catappa concluded that a flavonoid present in its leaf extract, namely kaempferol, possesses antiangiogenic properties. A significant reduction in the formation of new blood vessels in the chorioallantoic membrane of chick embryo was demonstrated after treatment with leaf extract of T. catappa in a dose-dependent manner. The molecular mechanism behind this activity has been elucidated as reduction in the gene expression of VEGF at both transcriptional and translational levels via both HIF (hypoxia-inducible factor)-dependent and HIF-independent pathways. The former includes the suppression of phosphorylation of Akt while the latter includes inhibition of mRNA level of ESRRA, a HIF-independent VEGF regulator. [49, 50] Terminalia catappa extracts have also shown antiangiogenic properties by inhibition of several angiogenic mediators such as MMP-9, urokinase-type plasminogen activator and their endogenous inhibitors, specifically tissue inhibitor of MMP-2, plasminogen activator inhibitor-1 and activator protein-1 (AP-1) in several anticancer studies and demonstrated attenuation in cellular proliferation and migration in several cell lines, but the same effects have not yet been tested for diabetes-induced angiogenesis. [28, 51, 52] As some of these mentioned angiogenic mediators are also involved in the pathophysiology of diabetic retinopathy and other angiogenic conditions induced during hyperglycaemia, further research is needed to explore whether the inhibition of these mediators by T. catappa produces similar antiangiogenic effects during hyperglycaemia and prevent the progression of diabetic microvascular complications.
Although reduction in inflammation is one of the requirements to prevent the incidence of diabetes and its complications, it is not the only requirement, and sole control on inflammation does not produces any significant clinical outcomes. To control hyperglycaemia, better approaches such as inhibition of sodium-glucose transport protein 2 (SGLT2) and agonism of glucagon-like peptide 1 (GLP-1) are being adopted as therapeutic options. However, unfortunately, T. catappa does not produce any of these two mentioned effects.
Terminalia catappa lowers cholesterol and serum low-density lipoprotein cholesterol levels
A number of studies have reported lipid level-altering abilities of T. catappa. These studies concluded that treatment of T. catappa during dyslipidaemia restores the normal lipid profile in liver and kidney tissues as well as in serum by either enhancing lipogenesis or reducing lipolysis, or both. [53] Decrease in the level of HDL (high-density lipoprotein) cholesterol due to unparalleled increase in the LDL cholesterol levels is a feature common to both hyperglycaemia and tumorigenesis. Similar to in-vitro (lymphocytes culture) and in-vivo (bone marrow cells of Albino mice) carcinogenic and mutagenic models, diabetesinduced dyslipidaemia is also characterized by abnormally high levels of triglycerides (due to increased lipolysis), along with high LDL cholesterol and low HDL cholesterol concentrations. [27, 54] Hence, the lipid-profile restoring abilities of T. catappa may be tested upon diabetes-induced dyslipidaemic models for obtaining similar beneficial effects. A number of mechanisms have been proposed to explain the stated lipid dysfunction during diabetes, among which inflammation-induced dyslipidaemia is a widely accepted hypothesis. TNF-a, secreted by adipocytes in response to hyperglycaemia-induced various pathological stimuli during diabetes mellitus, induces dyslipidaemic responses in adipose tissue, which include downregulation of peroxisome proliferator-activated receptor-gamma (PPAR-c) and elevation in free fatty acid levels via upregulating lipolysis. The above-mentioned two pathways have also been touted as the possible mechanisms for obesityinduced diabetes mellitus. As PPAR-c receptor is critical for the regulation of lipid and glucose metabolism and its agonism offers a number of protective actions against pathological inflammation, its downregulation by TNF-a via pathways such as IKK/NF-jB, MAPK (JNK, ERK, and p38) and apoptosis pathway renders target cells unprotected against inflammatory responses. [55, 56] Moreover, low HDL cholesterol level has been found to be an independent risk factor for the pathogenesis of diabetic nephropathy. [57] A copious hydrolysable tannin component present in T. catappa, punicalagin, reduces the production of TNF-a (as already discussed in the previous section), thereby downregulating the TNF-a-induced dyslipidaemic responses. Besides, it also increases the production of certain short-chain fatty acids (SCFAs) by enhancing the growth activity and metabolic activity of some commensal bacteria, namely Bifidobacterium breve and Bifidobacterium infantis. SCFAs are the metabolic products of these bacteria and act as endogenous agonists of PPAR-c receptors, and hence upregulate the elicitation of PPAR-c-mediated beneficial responses, viz., maintaining homoeostasis in lipid and glucose metabolism, suppression of inflammation and attenuating hyperglycaemia-induced dyslipidaemia. [58] Apart from the hydrolysable tannin, a flavonoid (quercetin) and a triterpenoid (ursolic acid) present in T. catappa were also found to possess lipid content-altering activity. Both quercetin and ursolic acid are hypocholesterolaemic in nature, but the mechanism by which each reduces the cholesterol content is different from the other. The former reduces the cellular biosynthesis of cholesterol by probably inhibiting the activity of HMG CoA (3-hydroxy 3-methylglutaryl coenzyme A) reductase (an enzyme which catalyses the rate-limiting step in cholesterol biosynthesis, viz., conversion of 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate) while the latter accelerates the bioconversion of cholesterol into bile acid by increasing the mRNA expression of an enzyme -cholesterol 7a-hydroxylase. Studies have shown that cholesterol 7a-hydroxylase is critical for the maintenance of cholesterol homoeostasis. It catalyses the conversion of cholesterol to bile acid and prevents cholesterol loading by acetyl-LDL. Hence, the overall synergistic action of quercetin and ursolic acid reduces the cholesterol content which subsequently signals an upregulation of hepatic LDL receptors, thereby increasing hepatic clearance of circulatory LDL particles. Therefore, quercetin and ursolic acid ultimately reduce total plasma LDL cholesterol levels and thus may potentially be utilized for the prevention of diabetic nephropathy. [53, 59] Another triterpenoid present in T. catappa, named asiatic acid, also presented similar LDL cholesterol-lowering activity by reducing the expression of HMG CoA reductase enzyme and subsequently decreasing increased plasma glucose, total cholesterol, triglycerides, free fatty acids, phospholipids, low-density lipoprotein, very low density lipoprotein, atherogenic index and increasing insulin and high-density lipoprotein in animal models of streptozotocin (STZ)-induced diabetes, thus demonstrating antidiabetic and antihyperlipidaemic properties. [60] Another recent study concluded that administration of a decoction of T. catappa (containing tannins, flavonoids, saponins, b-carotene, thiocyanates, cardiac glycosides, alkaloids, cyanogenic glycosides, vitamin C, q-hydroxybenzoic acid, alkaloids, catechins, free amino acids and monosaccharides) in Wistar rats resulted in improvement in the lipid profile by preventing the oxidation of LDL, reducing elevated serum total cholesterol, triacylglycerol, VLDL cholesterol, serum LDL cholesterol levels and augmenting the production of HDL and phospholipids. HDL is associated with the destruction of oxidized LDL while phospholipids are an important constituent of bile which helps in the solubilizing of cholesterol due to their detergent action. [22] The above-mentioned discussion clearly indicates that various phytoconstituents present in T. catappa contribute in improving the hyperglycaemiainduced dyslipidaemia and hence may be used for the prevention of subsequent dyslipidaemia-induced diabetic complications.
Terminalia catappa alters enzymatic activity related to glucose absorption
Numerous studies exploring antidiabetic properties of the leaf extract of T. catappa have reported its direct blood glucose-lowering effects, independent of any of the mechanisms discussed earlier. The mechanism behind this observed action has been postulated as the presence of certain chemical constituents in its leaf extract which possess the ability to inhibit activity of two major enzymes involved in carbohydrate digestion, namely a-glucosidase and a-amylase. [61] The former is present in the brush border of small intestine while the latter constitutes one of the enzymes in salivary and pancreatic digestive juices. Both these enzymes perform similar function, viz., catalysing the breakdown of complex dipolysaccharides, tripolysaccharides and polysaccharides into simpler glucose molecules by acting upon 1, 4-alpha glycosidic bonds. Hence, their enzymatic action aids in the formation of glucose from the dietary carbohydrates which is quite easily absorbed systemically by simple passive diffusion, ultimately raising blood glucose levels. [62] Although this process holds physiological importance in normal digestion of carbohydrates, it becomes a pathway that needs to be suppressed during conditions like diabetes mellitus. Indeed, blocking glucose absorption from the digestive tract by inhibiting the activity of one/both of these enzymes forms one of the successful approaches being used to clinically treat hyperglycaemia nowadays. Researchers aiming at developing natural antidiabetic therapies are exploring different plants species for obtaining active phytoconstituents having potential to inhibit any of these enzymes. [63] Terminalia catappa is one such plant which has experimentally proven its relevance in this regard. Several phytochemicals present in T. catappa such as phenolic compounds, flavonoids and triterpenoids can inhibit enzymatic activity of a-glucosidase and a-amylase.
According to in-vitro studies, phenolic hydrolysable tannin (punicalagin) is a strong inhibitor of a-glucosidase whereas its inhibitory action on a-amylase is very weak. Binding to the enzyme has been proposed as the possible mechanism for its inhibitory effect. [64] The flavonol compounds (quercetin and kaempferol) present in T. catappa also possess potent inhibitory action against yeast-derived a-glucosidase. However, their effect on pancreatic rat a-glucosidase was quite weak while inhibition of porcine pancreatic a-amylase was highly efficacious. [65] The pentacyclic triterpenoid (ursolic acid) inhibits both a-glucosidase [66] and a-amylase. [67] Studies conducted to investigate the mechanism behind these inhibitory effects concluded that flavonoids and triterpenoids compete with these enzymes for substrates. Flavonoids are reported to exhibit competitive and triterpenoids show non-competitive a-glucosidase inhibition, [68] while the reverse has been found in case of a-amylase inhibition. [67, 69] Although the various phytoconstituents (e.g. punicalagin, quercetin, kaempferol, ursolic acid) whose enzymeinhibiting effects are reported were obtained from plant species other than T. catappa, such as Pomegranate (Punica granatum Linn), [64, 66] Phyllanthus amarus [67] and Agrimonia Pilosa Ledeb, [68] as the same constituents are also present in T. catappa, identical results are expected. Nonetheless, experimental research on the same constituents extracted from T. catappa is still needed to be conducted to validate the same.
Conclusion
Diabetes is associated with hyperglycaemia which further acts as a harbinger for a number of pathological conditions including free radical damage and inflammation. The former causes apoptosis of various cell types and lipid peroxidation while the latter is responsible for endothelial dysfunction and angiogenesis. Besides, hyperglycaemia alters the lipid levels by increasing LDL cholesterol levels whereas HDL cholesterol levels remain uncompensated. Studies exploring the antidiabetic properties of T. catappa have concluded that this plant possesses the ability to reverse all the mentioned hyperglycaemia-induced pathological changes by inhibiting mitochondrial dysfunction, reducing superoxide production, downregulating the expression of various inflammatory and angiogenic factors and restoring the balance between the levels of LDL cholesterol and HDL cholesterol. Moreover, treatment of its leaf extract can even decrease hyperglycaemia, at the first place, by inhibiting the activity of enzymes involved in glucose absorption. Hence, treatment with T. catappa may provide an effective alternative natural therapy for hyperglycaemia and prevention of the progression of associated diabetic complications.
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